Clinical Trial

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2025 (before its estimated January 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-13; most recent amendment 2025-12-18.
Status change: Active, Not Recruiting → Recruiting 2025-12-18
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-08-19
Trial Details
NCT Number NCT06982352
Lead Sponsor LAPIX Therapeutics Inc.
Conditions Atopic Dermatitis (AD), Psoriasis (PsO)
Enrollment 48 participants
Start Date 2025-06-15
Primary Completion 2026-01-15 (estimated)
Study Completion 2026-04-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-19